Expanding the spectrum of megalencephalic leukoencephalopathy with subcortical cysts in two patients with GLIALCAM mutations

Tanit Arnedo, Chiara Aiello, Elena Jeworutzki, Maria Lisa Dentici, Graziella Uziel, Alessandro Simonati, Michael Pusch, Enrico Bertini, Raúl Estévez

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a heterogeneous neurodegenerative leukodystrophy caused by recessive mutations in MLC1 or GLIALCAM (types MLC1 and MLC2A) of by dominant mutations in GLIALCAM (MLC2B). GlialCAM functions as an auxiliary subunit of both MLC1 and ClC-2 chloride channel, increasing and modifying the function of the latter. Dominant mutations in GLIALCAM cause transient features of MLC but lacks clinical deterioration. Most recessive and dominant mutations in GLIALCAM studied so far affect the targeting of GlialCAM and its associated subunits. Here, we have investigated two patients with MLC2. The first patient has MLC2B disease, as shown by the improvement in MRI and clinical parameters. In this case, we identified a novel GLIALCAM mutation (p.Q56P) which affected the localization of GlialCAM and its associated subunits, however activating ClC-2 function as the wild-type protein. The second patient has MLC2A disease, as indicated by the lack of clinical improvement, even though, interestingly, the MRI of this patient shows a partial improvement. In this case, we found a recessive mode of inheritance, as the patient harbors two compound heterozygous mutations in GLIALCAM. One of them introduces a stop codon (p.Q56X), whereas the second mutation is a missense mutation (p.R73W), for which we could not identify any trafficking defect or an altered functional effect on ClC-2 in vitro.

Original languageEnglish
Pages (from-to)41-48
Number of pages8
JournalNeurogenetics
Volume15
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Mutation
Terminator Codon
Missense Mutation
Megalencephalic leukoencephalopathy with subcortical cysts
Proteins

Keywords

  • ClC-2
  • GLIALCAM
  • Leukodystrophy
  • MLC
  • MLC1
  • Remitting phenotype

ASJC Scopus subject areas

  • Genetics(clinical)
  • Cellular and Molecular Neuroscience
  • Genetics

Cite this

Expanding the spectrum of megalencephalic leukoencephalopathy with subcortical cysts in two patients with GLIALCAM mutations. / Arnedo, Tanit; Aiello, Chiara; Jeworutzki, Elena; Dentici, Maria Lisa; Uziel, Graziella; Simonati, Alessandro; Pusch, Michael; Bertini, Enrico; Estévez, Raúl.

In: Neurogenetics, Vol. 15, No. 1, 2014, p. 41-48.

Research output: Contribution to journalArticle

Arnedo, Tanit ; Aiello, Chiara ; Jeworutzki, Elena ; Dentici, Maria Lisa ; Uziel, Graziella ; Simonati, Alessandro ; Pusch, Michael ; Bertini, Enrico ; Estévez, Raúl. / Expanding the spectrum of megalencephalic leukoencephalopathy with subcortical cysts in two patients with GLIALCAM mutations. In: Neurogenetics. 2014 ; Vol. 15, No. 1. pp. 41-48.
@article{2a06a6d407b44451a3fe0aeb038ac7c5,
title = "Expanding the spectrum of megalencephalic leukoencephalopathy with subcortical cysts in two patients with GLIALCAM mutations",
abstract = "Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a heterogeneous neurodegenerative leukodystrophy caused by recessive mutations in MLC1 or GLIALCAM (types MLC1 and MLC2A) of by dominant mutations in GLIALCAM (MLC2B). GlialCAM functions as an auxiliary subunit of both MLC1 and ClC-2 chloride channel, increasing and modifying the function of the latter. Dominant mutations in GLIALCAM cause transient features of MLC but lacks clinical deterioration. Most recessive and dominant mutations in GLIALCAM studied so far affect the targeting of GlialCAM and its associated subunits. Here, we have investigated two patients with MLC2. The first patient has MLC2B disease, as shown by the improvement in MRI and clinical parameters. In this case, we identified a novel GLIALCAM mutation (p.Q56P) which affected the localization of GlialCAM and its associated subunits, however activating ClC-2 function as the wild-type protein. The second patient has MLC2A disease, as indicated by the lack of clinical improvement, even though, interestingly, the MRI of this patient shows a partial improvement. In this case, we found a recessive mode of inheritance, as the patient harbors two compound heterozygous mutations in GLIALCAM. One of them introduces a stop codon (p.Q56X), whereas the second mutation is a missense mutation (p.R73W), for which we could not identify any trafficking defect or an altered functional effect on ClC-2 in vitro.",
keywords = "ClC-2, GLIALCAM, Leukodystrophy, MLC, MLC1, Remitting phenotype",
author = "Tanit Arnedo and Chiara Aiello and Elena Jeworutzki and Dentici, {Maria Lisa} and Graziella Uziel and Alessandro Simonati and Michael Pusch and Enrico Bertini and Ra{\'u}l Est{\'e}vez",
year = "2014",
doi = "10.1007/s10048-013-0381-x",
language = "English",
volume = "15",
pages = "41--48",
journal = "Neurogenetics",
issn = "1364-6745",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Expanding the spectrum of megalencephalic leukoencephalopathy with subcortical cysts in two patients with GLIALCAM mutations

AU - Arnedo, Tanit

AU - Aiello, Chiara

AU - Jeworutzki, Elena

AU - Dentici, Maria Lisa

AU - Uziel, Graziella

AU - Simonati, Alessandro

AU - Pusch, Michael

AU - Bertini, Enrico

AU - Estévez, Raúl

PY - 2014

Y1 - 2014

N2 - Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a heterogeneous neurodegenerative leukodystrophy caused by recessive mutations in MLC1 or GLIALCAM (types MLC1 and MLC2A) of by dominant mutations in GLIALCAM (MLC2B). GlialCAM functions as an auxiliary subunit of both MLC1 and ClC-2 chloride channel, increasing and modifying the function of the latter. Dominant mutations in GLIALCAM cause transient features of MLC but lacks clinical deterioration. Most recessive and dominant mutations in GLIALCAM studied so far affect the targeting of GlialCAM and its associated subunits. Here, we have investigated two patients with MLC2. The first patient has MLC2B disease, as shown by the improvement in MRI and clinical parameters. In this case, we identified a novel GLIALCAM mutation (p.Q56P) which affected the localization of GlialCAM and its associated subunits, however activating ClC-2 function as the wild-type protein. The second patient has MLC2A disease, as indicated by the lack of clinical improvement, even though, interestingly, the MRI of this patient shows a partial improvement. In this case, we found a recessive mode of inheritance, as the patient harbors two compound heterozygous mutations in GLIALCAM. One of them introduces a stop codon (p.Q56X), whereas the second mutation is a missense mutation (p.R73W), for which we could not identify any trafficking defect or an altered functional effect on ClC-2 in vitro.

AB - Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a heterogeneous neurodegenerative leukodystrophy caused by recessive mutations in MLC1 or GLIALCAM (types MLC1 and MLC2A) of by dominant mutations in GLIALCAM (MLC2B). GlialCAM functions as an auxiliary subunit of both MLC1 and ClC-2 chloride channel, increasing and modifying the function of the latter. Dominant mutations in GLIALCAM cause transient features of MLC but lacks clinical deterioration. Most recessive and dominant mutations in GLIALCAM studied so far affect the targeting of GlialCAM and its associated subunits. Here, we have investigated two patients with MLC2. The first patient has MLC2B disease, as shown by the improvement in MRI and clinical parameters. In this case, we identified a novel GLIALCAM mutation (p.Q56P) which affected the localization of GlialCAM and its associated subunits, however activating ClC-2 function as the wild-type protein. The second patient has MLC2A disease, as indicated by the lack of clinical improvement, even though, interestingly, the MRI of this patient shows a partial improvement. In this case, we found a recessive mode of inheritance, as the patient harbors two compound heterozygous mutations in GLIALCAM. One of them introduces a stop codon (p.Q56X), whereas the second mutation is a missense mutation (p.R73W), for which we could not identify any trafficking defect or an altered functional effect on ClC-2 in vitro.

KW - ClC-2

KW - GLIALCAM

KW - Leukodystrophy

KW - MLC

KW - MLC1

KW - Remitting phenotype

UR - http://www.scopus.com/inward/record.url?scp=84897954507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897954507&partnerID=8YFLogxK

U2 - 10.1007/s10048-013-0381-x

DO - 10.1007/s10048-013-0381-x

M3 - Article

C2 - 24202401

AN - SCOPUS:84897954507

VL - 15

SP - 41

EP - 48

JO - Neurogenetics

JF - Neurogenetics

SN - 1364-6745

IS - 1

ER -